Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $42.43 Consensus PT from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $42.4286.

A number of research firms have recently weighed in on VRDN. UBS Group began coverage on Viridian Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target for the company. Needham & Company LLC raised their price objective on shares of Viridian Therapeutics from $34.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Evercore ISI reiterated an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, January 20th. William Blair started coverage on shares of Viridian Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating on the stock. Finally, Royal Bank Of Canada raised their price target on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, November 6th.

Viridian Therapeutics Trading Down 0.1%

Shares of NASDAQ:VRDN opened at $33.57 on Friday. The firm has a fifty day moving average of $32.06 and a two-hundred day moving average of $24.60. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.07. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $34.29. The firm has a market capitalization of $3.20 billion, a P/E ratio of -11.12 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.48. The business had revenue of $70.57 million during the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The firm’s quarterly revenue was up 81993.0% on a year-over-year basis. On average, equities analysts expect that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 2,272 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.58% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd bought a new position in shares of Viridian Therapeutics in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC grew its stake in Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after buying an additional 1,491 shares during the last quarter. Bessemer Group Inc. grew its stake in Viridian Therapeutics by 947.7% in the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after buying an additional 1,886 shares during the last quarter. Larson Financial Group LLC bought a new position in Viridian Therapeutics in the 3rd quarter worth $52,000. Finally, US Bancorp DE lifted its position in Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after acquiring an additional 463 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.